Acurx Pharmaceuticals, Inc.
ACXP
$3.48
$0.206.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.39% | 12.58% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.62% | 5.61% | |||
| Operating Income | 10.62% | -5.61% | |||
| Income Before Tax | 11.29% | -4.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.29% | -4.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.29% | -4.52% | |||
| EBIT | 10.62% | -5.61% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 35.05% | 12.02% | |||
| Normalized Basic EPS | 35.05% | 12.02% | |||
| EPS Diluted | 35.05% | 12.02% | |||
| Normalized Diluted EPS | 35.05% | 12.02% | |||
| Average Basic Shares Outstanding | 36.59% | 18.80% | |||
| Average Diluted Shares Outstanding | 36.59% | 18.80% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||